Signaling pathways
-
BA6329 BLU-945Summary: BLU-945 is a potent, highly selective, reversible epidermal growth factor receptor tyrosine kinase inhibitor (TKIs) with oral activity. - BA6330 LazertinibSummary: A potent, reversible, orally available, blood-brain barrier-crossing, mutant-selective, third-generation tyrosine kinase inhibitor.
- BA6331 SunvozertinibSummary: Sunvozertinib (DZD9008) is a potent (EGFR, Her2, especially mutant) inhibitor.
- BA6332 TX1-85-1Summary: TX1-85-1 is an irreversible inhibitor.
- BA6333 BI-4020Summary: BI-4020 is a fourth generation, orally active, non-covalent tyrosine kinase inhibitor.
- BA6334 MavelertinibSummary: Mavelertinib is a selective, orally effective and irreversible tyrosine kinase inhibitor with values of 5, 4, 12 and 3 nM for Del, L858R and double mutant T790M/L858R and T790M/Del, respectively.
- BA6335 PF-06459988Summary: PF-06459988 is an orally active, irreversible and mutant-selective mutant inhibitor.
- BA6336 ZenocutuzumabSummary: Zenocutuzumab (MCLA-128) is a bispecific humanized antibody.
- BA6337 RezivertinibSummary: Rezivertinib (BPI-7711) is an orally effective, highly selective and irreversible third-generation tyrosine kinase inhibitor (TKI).
- BA6338 BI-4142Summary: BI-4142 is a potent and highly selective inhibitor with oral activity.